UPDATE: Piper Jaffray Raises PT to $24 on NuVasive; Q4 Sets Stage for Outperformance
Piper Jaffray maintained NuVasive (NASDAQ: NUVA) with an Overweight rating and raised the price target from $23.00 to $24.00.
Piper Jaffray noted, "Management delivered surprising upside on a nice bounce-back in revenues in 4Q12. However, the challenge for NuVasive going forward will be to string together 3-4 quarters of meeting or beating estimates and to drive growth into the double-digit range that management has framed out for investors as an aspirational long-term objective, which, based on management's comments, will require continued cooperation from the spine market in terms of further improvements in growth. … We do in fact expect continued improvements in spine market growth in 2013 and we remain buyers of NUVA at current levels."
NuVasive closed at $18.42 on Tuesday.
Latest Ratings for NUVA
|Apr 2016||Cowen & Company||Maintains||Outperform|
|Dec 2015||Bank of America||Upgrades||Underperform||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.